Literature DB >> 19445785

Raynaud's phenomenon (primary).

Janet Elizabeth Pope1.   

Abstract

INTRODUCTION: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor followed by cyanosis and redness with pain and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in some cases of the ears or nose). This review focuses on primary (idiopathic) Raynaud's phenomenon occurring in the absence of an underlying disease. The prevalence of primary Raynaud's phenomenon varies by sex, country, and exposure to workplace vibration. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for primary Raynaud's phenomenon? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amlodipine, diltiazem, exercise, inositol nicotinate, keeping warm, moxisylyte (thymoxamine), naftidrofuryl oxalate, nicardipine, nifedipine, prazosin, and smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19445785      PMCID: PMC2907991     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  27 in total

1.  A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon.

Authors:  A E Smyth; A E Hughes; I N Bruce; A L Bell
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

2.  Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.

Authors:  Mirko Hirschl; Katharina Hirschl; Matthias Lenz; Reinhold Katzenschlager; Hans-Peter Hutter; Michael Kundi
Journal:  Arthritis Rheum       Date:  2006-06

3.  The occurrence of Raynaud's phenomenon in a general population: the Framingham Study.

Authors:  F N Brand; M G Larson; W B Kannel; J M McGuirk
Journal:  Vasc Med       Date:  1997-11       Impact factor: 3.239

4.  Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.

Authors:  T Gjørup; H Kelbaek; O J Hartling; S L Nielsen
Journal:  Am Heart J       Date:  1986-04       Impact factor: 4.749

5.  A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.

Authors:  A Rhedda; J McCans; A R Willan; P M Ford
Journal:  J Rheumatol       Date:  1985-08       Impact factor: 4.666

6.  Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up.

Authors: 
Journal:  Arch Intern Med       Date:  2000-04-24

7.  Prevalence of Raynaud's phenomenon in Great Britain and its relation to hand transmitted vibration: a national postal survey.

Authors:  K T Palmer; M J Griffin; H Syddall; B Pannett; C Cooper; D Coggon
Journal:  Occup Environ Med       Date:  2000-07       Impact factor: 4.402

8.  Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases.

Authors:  G Spencer-Green
Journal:  Arch Intern Med       Date:  1998-03-23

9.  A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.

Authors:  D O Corbin; D A Wood; C C Macintyre; E Housley
Journal:  Eur Heart J       Date:  1986-02       Impact factor: 29.983

10.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.